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Abstract
Background: Existing guidelines recommend different
strategies to prevent early-onset neonatal GBS sepsis. In
1997, using our own data on incidence and risk factors,
we established a new prevention strategy which includes
GBS screening at 36 weeks’ gestation and intrapartum
antibiotic prophylaxis (IAP) in women with positive or
unknown GBS colonization with at least one risk factor.
The present study evaluates the efficacy of the new pre-
vention strategy.
Methods: Retrospective study of the incidence of early-
onset GBS sepsis among all live births at the University
Women’s Hospital Basel between 1997 and 2002. Addi-
tional analysis of delivery and post partum period of all
GBS sepsis cases, including GBS screening, risk factors
during labor (prematurity, rupture of membranes (ROM)
-12 h, intrapartum signs of infection), and IAP. Compar-
ison of this group’s characteristics G2 (9,385 live births,
using the new strategy) with the previous group, G1
(1984–1993, 16,126 live births, without GBS screening or
routine IAP) was performed.
Results: The incidence of early-onset GBS sepsis was
reduced from 1/1000 (G1) to 0.53/1000 (G2). We observ-
ed a significant reduction of overall intrapartum risk
factors in cases of GBS sepsis.
Conclusion: This study suggests that our new preven-
tion strategy is effective in reducing the incidence of
early-onset GBS sepsis in neonates. In comparison,
implementation of the CDC’s prevention strategy might
have prevented 2 additional cases in 9385 live births.
However, this would have required treating a much larger
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number of pregnant women with IAP with consequential
increasing costs, side effects and complications.
Keywords: Antibiotic prophylaxis; early onset sepsis;
female; group B streptococcus; newborn; pregnancy
complications; risk factors; streptococcal infections/pc
wprevention & controlx; streptococcus agalactiae;
Switzerland.
Introduction
Group B streptococcus (GBS) first emerged as an impor-
tant pathogen in the 1970s. Subsequently, early-onset
GBS sepsis (in infants less than seven days old) became
the leading cause of sepsis in newborns and one of the
most common causes of neonatal infectious morbidity
and mortality w13, 18x.
At any given time, between 10 and 30% of women in
the United States are colonized with GBS w18, 26x. The
prevalence of colonization in Switzerland, as in other Eur-
opean countries, is 5–15% w23–25x. Although GBS col-
onization in the gastrointestinal and genital tracts of
women is most often asymptomatic, transient and does
not require treatment, GBS can nevertheless cause uri-
nary tract, skin, and soft tissue infections (including cho-
rioamnionitis, endometritis and postpartum wound
infections), or sepsis w12, 18x. During delivery, maternal
vaginal colonization with GBS is an important risk factor
for early-onset neonatal GBS sepsis. About half of the
infants born to colonized mothers become colonized on
their skin and mucosal surfaces as a result of passing
through the birth canal or from GBS ascending into the
amniotic fluid. One to two percent of the colonized
infants will develop early-onset disease. GBS sepsis has
been reported in 0.2–3.0/1000 births in the US and in
some European countries w20, 23x. Mortality between 4
and 10% and neurological sequelae, such as long-term
hearing loss, impaired vision, and developmental pro-
blems in 10–20% are observed w18, 20, 23x.
In addition to maternal GBS carrier status, prematurity
(onset of labor -37 completed weeks), prolonged rup-
ture of membranes (ROM )18 h after onset of labor), or
intrapartum fever ()100.48F/388C) have been identified
as risk factors for early-onset neonatal GBS sepsis. GBS
bacteriuria during a current pregnancy reflects heavy col-
onization and is considered a risk factor, as is a previous
delivery of an infant with early-onset GBS sepsis w12, 18x.
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Table 1 Risk-based versus Screening-based approach to prevent neonatal early-onset GBS sepsis as recommended by CDC in
1996 w2x.
Risk-based Screening-based
Screening No 35–37 weeks gestation
Risk factors – Prolonged ROM ()18 h) Same as in risk based
– Preterm delivery (-37 weeks gestation) approach
– Maternal intrapartum fever ()100.38F or 37.98C)
– GBS bacteriuria
– Previous neonate with early-onset GBS sepsis
IAP – If risk factor present If GBS positive
– If GBS bacteriuria or previous neonate independent of risk factor
with early-onset GBS sepsis If GBS unknown and
presence of risk factor
Since 1992, international attempts have been made to
establish guidelines for preventing early-onset neonatal
GBS sepsis w2, 10, 24x. Detection of maternal GBS carrier
status and/or of intrapartum risk factors have been the
main focus in these guidelines (Table 1). Asymptomatic
colonization can be determined by culturing the bacteria
from the vagina and the rectum. Culturing techniques
have recently improved, and prenatal cultures taken late
in pregnancy (35–37 weeks) can predict colonization
status at delivery w26x. Timely detection of maternal col-
onization during labor is not currently feasible, given the
low reliability of commercially available rapid tests w11x.
Intrapartum antibiotic prophylaxis (IAP) with penicillin as
the first line agent, administered to women at risk for
transmitting GBS to their newborns, has been shown to
decrease the risk of vertical transmission and early-onset
neonatal GBS sepsis w5, 18, 22x. However, concerns
related to IAP include costs, allergy (including anaphy-
lactic reactions) and microbial resistances w9, 18, 23x.
In 1995, aiming for prevention of early-onset neonatal
GBS sepsis, we determined the incidence of this com-
plication in our live births between 1984 and 1993, and
evaluated the risk factors among the affected cases w24x.
Based on our results, and taking into consideration
above mentioned concerns, we developed a new strat-
egy to prevent neonatal GBS sepsis, which was imple-
mented in our department in 1997. We established
screening between 35 and 37 weeks’ gestation and gave
IAP in GBS carriers who had an additional risk factor
(rupture of membranes more than 12 h, preterm delivery
and intrapartum signs of infection). IAP was also given in
case of unknown GBS colonization when another risk
factor was present, or in case a previous infant had con-
tracted GBS sepsis.
According to the revised CDC Guidelines from 2002,
the benefits of a screening-based approach (general
screening for GBS colonization, all women with positive
culture receive IAP) outweigh the above mentioned con-
cerns and is superior to a risk-based approach (IAP is
given in the presence of risk factors without screening)
w18x. The present study aimed to evaluate of the efficacy
of our screening and risk-factor directed strategy.
Material and Methods
Population and study design
We conducted a retrospective analysis in order to determine
the incidence of early-onset GBS sepsis among all live births at
the University Women’s Hospital Basel between 1997 and 2002.
In addition, analysis of delivery and postpartum period of the
GBS sepsis cases was performed. GBS carrier status, risk fac-
tors during labor and IAP were noted. This group (G2) of 9,385
live births had been managed by following our prevention man-
agement, implemented in 1997, which consisted of GBS screen-
ing at 35–37 weeks gestation (swab taken from the lower third
of the vagina, and processed using selective broth medium), risk
factor detection and administration of IAP in the presence of
GBS or unknown colonization plus an additional risk factor
(Table 2), or in case a previous child had contracted GBS sepsis.
We further compared our findings in this group (G2) with data
collected from another group of neonates (G1), born before this
new prevention management had been established. G1 included
16,126 live births during the years 1984–1993. Women in G1
had not been screened for GBS and had not received routine
IAP.
Data collection
Cases of early-onset GBS sepsis were identified from the data
bank of the department of pediatrics as well as of the microbi-
ology laboratory. Early-onset neonatal GBS sepsis was defined
as a positive blood culture with clinical symptoms appearing
within 7 days postpartum. Bacterial identification was estab-
lished according to the Manual of Clinical Microbiology following
NCCLS Guidelines of susceptibility testing w15x. The labor and
delivery records of the affected infants and their mothers were
reviewed. Summarized information for the cases included the
following variables: gestational age, GBS screening, clinical risk
factors (Table 2), previous infant with GBS sepsis, IAP, maternal
intra- and postpartum morbidity, and neonatal mortality. The
period between onset of labor or the ruptures of the membranes
and delivery was defined as the ‘‘intrapartum’’ period.
Statistical analysis
The software of Epi Info Version 3.2 w8x was used to calculate
risk ratios and their confidence intervals. For further testing of
significance the Chi-square test was used, and the 2-tailed Fis-
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Table 2 Management for prevention of neonatal early-onset GBS sepsis before and after introduction of a new prevention strategy.
Group G1 G2
(1984–1993, 16,126 live births) (1997–2002, 9,385 live births)
Management No screening GBS screening at 35–37 weeks’ gestation
No routine IAP IAP in case of:
– Positive or unknown GBS carrier
status and the presence of at least
one intrapartum risk factors (ROM
)12 h, delivery -37 weeks,
maternal intrapartum signs of
infection (temperature G388C, CRP
G20 mg/L, Leukocytosis G18,000/mL,
or persistent fetal tachycardia)
– Previous neonate with early-onset
GBS sepsis
Table 3 Comparison of early-onset neonatal GBS sepsis between the two groups G2 & G1.
G1 G2 P-values
Time period 1984–1993, 1997–2002
Live births (n) 16,126 9,385
Cases of GBS sepsis 16 5
Characteristics of cases and their mothers:
GBS colonization in cases 16= unknown 2= positive
2= negative
1= unknown
Risk factors**: 15/16 0/5 PF0.001*
Premature delivery 7/16 0/5 Ps0.12
Rupture of Membranes )12 h 11/16 0/5 Ps0.01*
Signs of amnionitis 7/16 0/5 Ps0.12
IAP 0/16 0/5
Mortality 1/16 0/5 Ps1
Mean gestational age (weeks) 37 40q2
Mean interval until positive 1.7 1.6
blood culture (days post partum)
Postpartum infection 7/16 0/5 Ps0.12
*P-values statistically significant (P-0.05).
** Women may have had more than one risk factor.
her’s exact test was used when the expected cell value was less
than 5.
Results
The present study at the University Women’s Hospital
Basel evaluated the incidence of early-onset neonatal
GBS sepsis in a total of 25,511 live births between the
years 1984–1993 (G1, 16,126 live births) and 1997–2002
(G2, 9,385 live births). Twenty-one cases were identified,
of which 16 occurred in G1, before prevention manage-
ment had been implemented (Table 3). After implemen-
tation of the prevention strategy we observed 5 cases
out of 9,385 live births. The incidence of early-onset GBS
sepsis decreased from 1/1000 (G1) to 0.53/1000 live
births (G2), and the Relative Risk (RR) of developing GBS
sepsis in G2 was 0.54 times the risk observed in G1. The
95% confidence interval (CI), however, included 1
(0.20–1.47), which was reflected in the statistically not
significant Chi-square test (Ps0.217) (Figure 1).
Table 3 compares the characteristics of early-onset
neonatal GBS sepsis between the two groups. As a result
of establishing a management in which women with pos-
itive or unknown GBS colonization and at least one risk
factor for GBS sepsis received IAP, we observed signifi-
cantly fewer risk factors present during delivery of the
neonates who developed GBS sepsis (Fisher exact test,
P-0.001). Particularly, reduction of ROM -12 h reached
statistical significance (Fisher exact test: Ps0.01). The
carrier status was still unknown in one of 5 term-born
cases of neonatal GBS sepsis in G2 indicating incom-
plete implementation of screening. None of the 5 cases
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Figure 1 Incidence and RR of early-onset neonatal GBS sepsis
in G1 compared to G2.
had an indication for IAP according to our management
and none received IAP. The case-fatality decreased from
one case, a preterm delivery, in G1 to no case in G2.
Two of the five infants who developed early-onset GBS
sepsis were born to mothers who had been screened
GBS positive. The first case was a male neonate, 3065 g,
born at 39q0 weeks gestation, by vacuum extraction for
bradycardia. He had good APGAR (9/10/10) scores and
cord blood pH, and initially appeared healthy. However,
subsequently he developed vomiting, gray skin, and his
CRP was increased. GBS was found in his blood culture
four days after delivery. Antibiotic therapy resulted in
rapid recovery. The second case was a male neonate,
4550 g, born at 41q1 weeks gestation, by vacuum
extraction for macrosomia and non-reassuring fetal mon-
itoring. Amniotic fluid contained meconium. APGAR
scores were 1, 7 and 10, and cord blood pH was good.
Soon after delivery, the neonate developed tachypnea
and became pale. His blood culture one day later
showed GBS. Antibiotic therapy with Augmentin and For-
tam resulted in gradual recovery.
Discussion
Early-onset group B streptococcal sepsis has been the
leading cause of neonatal sepsis and one of the most
common causes for neonatal infectious mortality in the
USA and Switzerland since the 1970s. Newly developed
prevention strategies with intrapartum antimicrobial pro-
phylaxis (IAP) effectively prevent the disease w2, 5, 18,
22x. However, concerns have been raised regarding
costs, side effects and complications from these strate-
gies; particularly screening and widely use of IAP w9, 18x.
The focus has been on how to best identify mothers and
infants at risk for being infected and women who should
receive intrapartum antibiotics.
In 1997 we implemented a new prevention strategy,
which was based on our own results regarding incidence
of early-onset neonatal GBS sepsis and its risk factors in
16,126 live births at our institution between 1984 and
1993 (G1) w24x. We established a screening program
between 35 and 37 weeks’ gestation and administered
IAP in GBS carriers only if they had an additional risk
factor (ROM more than 12 h, preterm delivery and mater-
nal intrapartum signs of infection). IAP was also given in
case of unknown GBS status in the presence of a risk
factor, or in case a previous child had contracted GBS
sepsis (Table 2). The evaluation of 9,385 live births (G2,
between 1997 and 2002) managed with our new strategy,
showed a decrease in the incidence of early-onset GBS
sepsis from 1/1000 (G1) to 0.53/1000 live births (G2). This
decrease was reflected in a RR of 0.54 in G2 compared
to G1. However, the 95% confidence interval (CI) includ-
ed 1 (0.20–1.47), and the p-value was not statistically
significant (Ps0.217) (Figure 1). This lack of statistical
significance of the result might be due to low power, a
limitation often encountered in the presence of a rare
disease.
Before the introduction of the US national guidelines,
an incidence of 2–3 cases of early-onset neonatal GBS
sepsis per 1000 live births was reported w18x. In 1996,
the American College of Obstetricians and Gynecolo-
gists, the American Academy of Pediatrics, and the Cen-
ters for Disease Control and Prevention (CDC) issued
guidelines for prevention, and recommended the use of
either a risk-based or a screening-based approach to
identify women for IAP (Table 1) w2x. Implementation of
the first guidelines coincided with a 65% decline in the
incidence of GBS sepsis between 1993 and 1998 (from
1.7 to 0.6/1000 live births) w20x.
Similar to our results, an evaluation of the 1996 Guide-
lines which included a large retrospective cohort study,
revealed an overall incidence of 0.5/1000 live births w19x.
Fifty-two percent of women in the cohort had been
screened for GBS. Further analysis showed that the risk
of GBS sepsis was significantly (-50%) lower among
infants of screened women than among those in the risk-
based group (adjusted RR 0.46; 95% CI 0.36, 0.6). Pro-
jections showed that 100% implementation of the
risk-based approach would have reduced the incidence
from 0.5/1000 to 0.44/1000 live births, whereas a 100%
implementation of screening-based approach would
have led to a further reduction with only 0.32 infections
per 1000 live births (95% CI 0.26, 0.38) w19x. Based on
the evaluation, revised guidelines were published in
2002, favoring the screening-based approach w1, 3, 4,
19x. By following this screening-based approach and
giving IAP to all GBS positive women, we could have
potentially prevented 2 cases of sepsis and would have
reduced the incidence to the 0.32/1000 live births in our
population (G2). This low incidence had been projected
by Schrag et al. in 2002 w19x and was observed in the
US in 2003 w6, 16x.
Schrag et al. w19x observed that in women with a pos-
itive GBS culture but without an additional risk factor,
who did not receive IAP, the incidence of disease was
1.3/1000 live births (95% CI 0.3, 2.8). The higher the per-
centage of these women in an obstetric population, the
more the overall incidence would approach 1.3/1000.
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Even though we follow the same management, our inci-
dence of GBS sepsis is much lower than 1.3/1000 live
births, probably because of the relatively lower preva-
lence (10–15%) of GBS colonization in Switzerland com-
pared to the 10–30% reported in the US w18, 23, 24x.
Availability of European data about maternal GBS col-
onization and incidence of neonatal GBS sepsis is limit-
ed. Colonization in most European countries ranges from
10 to 20% w25x; and respectively from 10 to 15% in
Swiss women w23–25x. A limitation of the present study
is that it was impossible to extract the percentage of GBS
screened women and the prevalence of GBS among our
study population from the charts.
In accordance with our findings, early-onset GBS sep-
sis in Europe develops in 0.3–2/1000 live births w25x.
Many European countries, including Switzerland, lack
national GBS sepsis prevention guidelines, but have
local protocols w25x. The German Society for Obstetrics
and Gynecology has adopted the CDC guidelines for pre-
vention of GBS sepsis in 2004, but recommend an eval-
uation of this management 2–3 years after its implemen-
tation w7x.
Further analysis showed that in accordance with our
new prevention guidelines none of our 5 GBS sepsis cas-
es in G2 had an indication for IAP, and therefore none
received IAP. This is supporting evidence for the actual
implementation of our new prevention strategy, also
reflected in a significant reduction of the presence of risk
factors in the cases compared to cases in the previous
time period (G1). GBS colonization was still unknown in
one of 5 term-born cases of neonatal GBS sepsis in G2,
indicating incomplete implementation of screening. Since
the CDC guidelines are complex, noncompliance has
been reported frequently; in up to 39% of cases with the
risk-based approach and 14% with the screening-based
approach. A US survey published in 2000 showed that
98% adopted a GBS policy, of which 69% used a version
of a screening approach and 26% used the risk-based
approach. Hospitals with any intensified prevention pol-
icy had a significant decline in incidence of early-onset
disease w9, 19x.
Our case-fatality decreased from one case, a preterm
delivery in G1 to none in G2. Due to improved neonatal
care, the survival of GBS sepsis improved in recent years
(from initially 50 to now 96%), but continues to be lower
in preterm infants w5, 9x.
Concerns about an optimal management are due to
costs of screening and IAP, as well as adverse effects of
IAP including allergic or anaphylactic reactions to IAP,
emergence of antimicrobial resistant GBS strains and
other pathogens, and an increased incidence of serious
neonatal infections caused by pathogens other than
GBS. Further issues of interest include improvement in
screening and development of vaccines w9x.
Cost-effective analyses in the US suggested that the
risk-based approach is equally cost effective or superior
to the screening-based approach w14, 17x. Rouse et al.
w17x calculated an 18% maternal treatment rate in the
risk-based approach, and 27% in the screening-based
approach. In both strategies total costs were estimated
to be similarly low. In contrast, Schrag et al. w19x showed
that the anticipated intrapartum antibiotic use did not dif-
fer between the screening and risk-based strategies,
when the both were implemented according to the CDC
recommendations. Under screening, an estimated 30%
of deliveries received intrapartum antibiotics for any
reason whereas under the risk-based approach 29%
received intrapartum antibiotics for any reason. Under
each strategy 24% of deliveries had an indication for
GBS prophylaxis. The authors did not present a cost-
effective analyses, but were in favor of the screening-
based approach, since it allowed for a broader coverage
of the at-risk population, capturing colonized women
without obstetric risk factors (18% of deliveries), which
resulted in a lower incidence of GBS sepsis compared to
the risk-based approach w19x. We assume that by follow-
ing our management we used less IAP than in either the
screening-based approach favored by CDC or the pure
risk-based approach, since we did not treat GBS-nega-
tive women even if presenting with risk factors, nor GBS-
positive women without additional risk factor. However,
in our study we could not obtain the actual frequency of
IAP. Ideally, the data on GBS screening and prevalence,
as well as IAP, would be collected in a prospective study.
A Swiss prospective cohort study based on cost-benefit
analysis came to an even more extreme conclusion. It
suggested that even though both the risk- and screen-
ing-based approaches recommended by the CDC were
more effective than their restrictive risk-based approach,
these approaches implied increased hospital costs and
a substantial increase in the proportion of women receiv-
ing antibiotics during labor, which may be unjustified in
a setting of low maternal GBS carrier status. They report-
ed an incidence of only 0.4/1000 live births, while only
treating 6.0% of women with antibiotics during labor.
Adopting the risk-based approach as defined by the CDC
they would have expected to treat 13.5% women and
16.5% with the screening-based approach w23x.
Wide use of antibiotics has been criticized for several
reasons. Resistance to clindamycin and erythromycin
increased among GBS isolates. Concerns have also
been raised regarding an emerging resistance of second
line agents. Most studies find stable or declining rates of
sepsis caused by other pathogens, whereas selected
populations, such as preterm and very low birth weight
neonates seem to be at a higher risk for sepsis caused
by resistant microorganisms w9, 21x. Data on changing
prevalence in resistant pathogens, i.e., E. coli, which
cause illness outside the context of the labor and delivery
setting, are controversial w21x.
Our results showed two cases of GBS sepsis in neg-
atively screened women. This may be explained by a pre-
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vious observation in which 15–20% of all women who
had negative second trimester cultures were subse-
quently colonized in the late third trimester or during
delivery w26x. Based on this concern, there has been a
great interest in development and implementation of rap-
id and sensitive techniques to screen for GBS coloniza-
tion and antibiotic susceptibility until effective vaccines
against GBS are available for clinical use w9, 16, 21x. Vac-
cine development has reached phase I and II, but pro-
ceeding to phase III has turned out to be difficult, due to
liability issues if tested in pregnant women w9x.
In summary, our management of screening all women,
but administering IAP only in women with an unknown
or positive GBS culture who have an additional risk fac-
tor, intends to reduce the use of antibiotics compared to
the screening-based approach suggested by the CDC.
The advantage of our management versus a pure risk-
based approach without screening is that IAP can be tai-
lored to women with a positive culture and risk factors,
versus treating everyone with a risk factor in the absence
of screening. Thereby, we exclude many women from
IAP. IAP causes more harm than screening, since in addi-
tion to costs, which results from screening as well as
from IAP, IAP has adverse affects including allergic reac-
tions and emergence of resistant pathogens. With this
approach we successfully decreased our incidence of
early-onset neonatal GBS sepsis to 0.53/1000 live births.
In order to reach the most recent reported incidence of
0.32/1000 live births in the US, we would have to adopt
the screening-based approach currently recommended
by CDC. However, this would mean giving IAP to many
more pregnant women. Our data suggest that guidelines
developed for the setting present in the US should not
be adopted uncritically, and that a modified strategy of
the CDC guidelines can be appropriate in a setting of
lower prevalence of GBS colonization. Without any
doubt, development of effective rapid tests and GBS
vaccines remain a priority.
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